![Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective](https://www.frontiersin.org/files/Articles/655054/fphar-12-655054-HTML-r1/image_m/fphar-12-655054-g001.jpg)
Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective
![PDF) Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts PDF) Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts](https://i1.rgstatic.net/publication/352170183_Effectiveness_and_Safety_of_Adalimumab_Biosimilar_SB5_in_IBD_Outcomes_in_Originator_to_SB5_Switch_Double_Biosimilar_Switch_and_Bio-Naieve_SB5_Observational_Cohorts/links/613515bfc69a4e48797d9ee2/largepreview.png)
PDF) Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts
![Janssen Demonstrates Strong Commitment to Advancing Science of Inflammatory Bowel Disease with Robust Selection of Data Presentations at 14th Congress of ECCO | Business Wire Janssen Demonstrates Strong Commitment to Advancing Science of Inflammatory Bowel Disease with Robust Selection of Data Presentations at 14th Congress of ECCO | Business Wire](https://www.sttinfo.fi/data/images/00301/cc734d3d-9449-43af-910f-effb76d21937-w_300_h_100.png)